title: Eating Disorder Examination-Questionnaire as a measure of change in patients with bulimia nervosa.
abstract: OBJECTIVE
  The current study evaluated the agreement between the Eating Disorder Examination and the Eating Disorder Examination-Questionnaire in assessing eating disorder pathology in a sample of women with bulimia nervosa.
  
  
  METHODS
  Patients with broadly defined bulimia nervosa were enrolled in a double-blind, placebo-controlled treatment study of fluoxetine, with and without guided self-help. The current study presents information from 50 patients with data from both the EDE and EDE-Q at study entry and treatment termination.
  
  
  RESULTS
  The EDE and EDE-Q produced more similar scores for compensatory behaviors (vomiting/laxative use) than complex eating-disordered features (binge eating/importance of shape and weight) at the pretreatment and posttreatment assessments, and for change during the study.
  
  
  CONCLUSIONS
  The EDE and EDE-Q are highly correlated for many of the behavioral and attitudinal features of bulimia nervosa. There is substantial variability in agreement for individual patients, but on average, the EDE and EDE-Q will yield similar assessments of eating disorder symptoms and change in symptoms over time.
authors.affiliation: Department of Psychology, Rutgers-The State University of New Jersey, 152 Frelinghuysen Road, Piscataway, NH 08854, USA. syskor@child.cpmc.columbia.edu
authors.forename: Robyn
authors.initials: R
authors.lastname: Sysko
authors.forename: B Timothy
authors.initials: BT
authors.lastname: Walsh
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Fairburn
mesh_terms: D000293:Adolescent; D000328:Adult; D002032:Bulimia / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology* / Q000628:therapy*; D039721:Diagnostic and Statistical Manual of Mental Disorders; D004311:Double-Blind Method; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D012657:Self-Help Groups; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires
chemical_list: D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors